Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients

March 2, 2016

Diversion and abuse of the medications used in opioid maintenance treatment (OMT) methadone (MET), mono-buprenorphine (BUP) and buprenorphine-naloxone (BNX) have been documented in countries around the world, for example in France (Auriacombe, Fatseas, Dubernet, Daulouede, & Tignol, 2004; Nordmann et al., 2012; Obadia, Perrin, Feroni, Vlahov, & Moatti, 2001; Roux et al., 2008a; Roux et […]

Read the full article →

A New Formulation of Buprenorphine/Naloxone

March 2, 2016

No abstract available (Source: Journal of Addictions Nursing)

Read the full article →

Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003

March 2, 2016

Opiate withdrawal scales were developed to examine the patient’s physical dependence and physiological readiness prior to methadone or buprenorphine induction, and to compare treatments for withdrawal (Wesson and Ling, 2003). The Clinical Opiate Withdrawal Scale (COWS; Wesson and Ling, 2003) is a common measure used to assess withdrawal in clinical trials and practice, and consists […]

Read the full article →

Prescription Opioid Misuse: Effective Methods for Reducing the Epidemic

March 2, 2016

Opinion statement Prescription opioid misuse has been a significant epidemic during the past decade. Formulations of prescription opioids with different mechanisms of abuse-deterrence have been developed or are currently under development. Given that these medications are substantially more difficult to use in an illicit fashion and minimize the potential for euphoria and/or create an aversive […]

Read the full article →

Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients

March 2, 2016

The high prevalence of interrelated problems with opioid use disorder, injection drug use (IDU), and HIV/AIDS in Malaysia has led to the scale-up of public health approaches, including opioid agonist maintenance treatment with buprenorphine or methadone. Malaysia has more than 300,000 registered people who use drugs (PWUD)-approximately 1.1% of its population of about 30 million-and […]

Read the full article →

Editor’s Message and Issue Highlights—March–April 2015

March 2, 2016

In this study, the authors specifically examined IA among subjects with obsessive-compulsive disorder (OCD). All enrolled patients with OCD alone (n=27) and OCD and IA (n=11) were treated for OCD for a period of one year. At 12 months, only two of the 11 patients with OCD and IA continued to meet the criteria for […]

Read the full article →

Starting Suboxone Therapy in the ED Benefits Opioid-Dependent Patients (FREE)

March 2, 2016

By Daniel J. Pallin, MD, MPH Opioid-dependent individuals visiting the emergency department are much more likely to participate in addiction treatment when buprenorphine/naloxone therapy is started during the visit, a JAMA study finds.Investigators randomized some 330 adult patients reporting opioid dependence to one of … (Source: Physician’s First Watch current issue)

Read the full article →

Cost burden analysis of relapse in prescription Opioid Drug dependent Patients treated with Buprenorphine/Naloxone and Patients without Pharmacological treatment

March 2, 2016

The objective of this study was to compare resource utilisation and associated healthcare costs between the OPD patients treated with buprenorphine/naloxone combination and OPD patients without pharmacological treatment from the German healthcare perspective. (Source: Value in Health)

Read the full article →

The introduction of buprenorphine‐naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations

March 2, 2016

ConclusionsThe introduction of BNX film in Australia varied across States. A perception of restricted choice in medication may have undermined initial acceptance in SA. [Larance B, Dietze P, Ali R, Lintzeris N, White N, Jenkinson R, Degenhardt L. The introduction of BNX film in opioid substitution therapy in Australia: Uptake and issues arising from changing […]

Read the full article →

Factors associated with willingness to take extended release naltrexone among injection drug users

March 2, 2016

Conclusions: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional […]

Read the full article →